| 彭海燕 唐惠芳.ADMA-- 一个新的心血管疾病危险因子[J].,2012,12(14):3797-3800 |
| ADMA-- 一个新的心血管疾病危险因子 |
| Asymmetric Dimethylarginine(ADMA)：A new risk factorfor Cardiovascular Disease |
| |
| DOI： |
| 中文关键词: ADMA 内皮功能障碍 心血管疾病 心功能不全 死亡率 |
| 英文关键词: asymmetric dimethylarginine, endothelial dysfunction, cardiovascular disease,heart failure, mortality |
| 基金项目:国家自然科学基金项目（30900625） |
|
| 摘要点击次数: 835 |
| 全文下载次数: 999 |
| 中文摘要: |
| 非对称性二甲基精氨酸（asymmetric dimethylarginine ，ADMA）为内源性一氧化氮合酶（endogenous Nitric-Oxide Synthase，
eNOS）竞争性抑制剂，可抑制NOS 的活性，减少一氧化氮（nitric oxide ，NO）的合成，致使内皮功能障碍。近年来研究认为ADMA
是冠心病的独立预测因子，与心功能不全及心血管疾病死亡率明显相关。本文将针对ADMA 与心血管疾病的相关性进行综述。 |
| 英文摘要: |
| As an endogenous nitric oxide synthase competitive inhibitor，asymmetric dimethylarginine (ADMA) can inhibit the
activity of nitric oxide synthase (NOS), reduce the synthesis of nitric oxide (NO) and result in endothelial dysfunction. In recent years,
studies suggest that ADMA is an independent predictor of coronary heart disease and it is significantly associated with heart failure and
mortality of cardiovascular disease. This article aims to review the relationship between plasma ADMA and cardiovascular disease. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
